Tilray, Inc. Series 2 is a premium stock of StocksGuide. Please log in to activate an alert for Tilray, Inc. Series 2.
Register for Free
Please register for free to add Tilray, Inc. Series 2 to your portfolio.
Tilray, Inc. Series 2 Stock News
$11.16
9.56%
yesterday
Nasdaq,
Dec 19, 10:17 pm CET
Why the stock moved Beta
StocksGuide Unlimited – full access to AI analyses
With Unlimited you get the full AI functionality for Tilray, Inc. Series 2. 👉 More detailed insights 👉 Exclusive perspectives on opportunities & risks 👉 Clear answers to your questions
Cannabis stocks sold off this week following President Trump's Executive Order directing marijuana's reclassification to Schedule III for increased medical and cannabidiol research. The sharp selloff highlights how fragile sentiment in cannabis stock remains, even amid policy progress. Further volatility is possible if regulatory implementation drags on or if broader market risk appetite weakens.
President Donald Trump's marijuana reclassification executive order followed a yearlong push by cannabis executives, billionaire allies and political operatives combining donations, lobbying and targeted polling, according to industry insiders. Trulieve CEO Kim Rivers and Palm Beach billionaire Howard Kessler leveraged personal ties, fundraisers and political spending to press the White House, ...
Analysts are now focused on the when the change will actually happen, as the cannabis industry waits for tax relief and expanded research opportunities.
Tilray Brands' stock performance hinges on the outlook for marijuana reform in the U.S. President Trump is considering rescheduling marijuana, which has investors bullish on Tilray of late. The company's financial results, however, show that marijuana revenue declined in its most recent fiscal year.
As On The Money has been reporting since April, our famously drug-and-drink-averse president has been inching ever closer to making marijuana significantly less criminal in the eyes of the federal government.
President Donald Trump's move to relax federal marijuana regulations has been welcomed by the US cannabis industry, but it has not changed the sector's most persistent challenge. Access to mainstream banking remains limited, even as regulatory pressure eases, reports Reuters.
U.S. President Donald Trump's move to relax marijuana regulations could ease some burden for cannabis companies, but will likely keep doors to access capital from big banks closed, experts said.
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.